Literature DB >> 23926460

Inherited predisposition to multiple myeloma.

Divya T Koura1, Amelia A Langston.   

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy in the United States, after non-Hodgkin lymphoma. Family pedigree analyses of high-risk families, case-control studies and racial disparities in disease incidence all point to a potential inherited predisposition to MM. Genome-wide association studies (GWASs) have identified susceptibility loci in a number of cancers and such studies are currently underway in MM. To date, GWASs in MM have identified several potential regions of interest for further study on chromosomes 3p22, 7p15.3, 8q24 and 2p23.3. In addition, several targets of paraproteins (so called 'paratargs') in MM have been identified. Hyperphosphorylation of the paratarg protein, which is inherited in an autosomal dominant manner, appears a common mechanism underlying the antigenicity of these proteins. One particular protein, hyperphosphorylated paratarg-7 (pP-7) is a common target in persons with myeloma and has also been identified in affected members of several high-risk MM families. It appears that the frequency of pP-7 as an antigenic target may be particularly high in African American patients with MM, which could be part of the explanation for observed racial disparities in the incidence of MM. In this review we focus on available data in the area of inherited predisposition to MM, and highlight future research directions.

Entities:  

Keywords:  Waldenström macroglobulinemia/genetics; autoantigens/genetics; genetic predisposition to disease; monoclonal gammopathy of undetermined significance/genetics; multiple myeloma/epidemiology; multiple myeloma/genetics; paraproteins/genetics; phosphorylation/physiology; risk factors

Year:  2013        PMID: 23926460      PMCID: PMC3734900          DOI: 10.1177/2040620713485375

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN: 2040-6207


  55 in total

1.  Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin.

Authors:  Goedele N Maertens; Peter Cherepanov; Alan Engelman
Journal:  J Cell Sci       Date:  2006-05-30       Impact factor: 5.285

2.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Authors:  Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

3.  HL-A antigen frequencies in myeloma.

Authors:  D Y Mason; P Cullen
Journal:  Tissue Antigens       Date:  1975-05

4.  Localization of the gene for familial adenomatous polyposis on chromosome 5.

Authors:  W F Bodmer; C J Bailey; J Bodmer; H J Bussey; A Ellis; P Gorman; F C Lucibello; V A Murday; S H Rider; P Scambler
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

5.  Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Alexandra Wikowicz; Evangelos Terpos; Marita Ziepert; Diana Nikolaus; Yin Yang; Natalie Fadle; Evi Regitz; Meletios A Dimopoulos; Steven P Treon; Zachary R Hunter; Michael Pfreundschuh
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

Review 6.  Multiple myeloma: a review of the epidemiologic literature.

Authors:  Dominik D Alexander; Pamela J Mink; Hans-Olov Adami; Philip Cole; Jack S Mandel; Martin M Oken; Dimitrios Trichopoulos
Journal:  Int J Cancer       Date:  2007       Impact factor: 7.396

7.  Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Stephan Thome; Dennis D Weisenburger; Vinetta Witt; Jane Lynch; Florian Zettl; Lorenz Trümper; Natalie Fadle; Evi Regitz; Henry Lynch; Michael Pfreundschuh
Journal:  Blood       Date:  2011-05-17       Impact factor: 22.113

8.  Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study.

Authors:  Sandra Grass; Klaus-Dieter Preuss; Manfred Ahlgrimm; Natalie Fadle; Evi Regitz; Claudia Pfoehler; Niels Murawski; Michael Pfreundschuh
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

9.  Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study.

Authors:  M Eriksson; B Hållberg
Journal:  Cancer Causes Control       Date:  1992-01       Impact factor: 2.506

10.  Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396

View more
  4 in total

1.  Direct evidence for a polygenic etiology in familial multiple myeloma.

Authors:  Britt-Marie Halvarsson; Anna-Karin Wihlborg; Mina Ali; Konstantinos Lemonakis; Ellinor Johnsson; Abhishek Niroula; Carrie Cibulskis; Niels Weinhold; Asta Försti; Evren Alici; Christian Langer; Michael Pfreundschuh; Hartmut Goldschmidt; Ulf-Henrik Mellqvist; Ingemar Turesson; Anders Waage; Kari Hemminki; Todd Golub; Hareth Nahi; Urban Gullberg; Markus Hansson; Björn Nilsson
Journal:  Blood Adv       Date:  2017-04-07

2.  Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium.

Authors:  Leah H Schinasi; Elizabeth E Brown; Nicola J Camp; Sophia S Wang; Jonathan N Hofmann; Brian C Chiu; Lucia Miligi; Laura E Beane Freeman; Silvia de Sanjose; Leslie Bernstein; Alain Monnereau; Jacqueline Clavel; Guido J Tricot; Djordje Atanackovic; Pierluigi Cocco; Laurent Orsi; James A Dosman; John R McLaughlin; Mark P Purdue; Wendy Cozen; John J Spinelli; Anneclaire J de Roos
Journal:  Br J Haematol       Date:  2016-06-22       Impact factor: 6.998

3.  The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

Authors:  Mina Ali; Ram Ajore; Anna-Karin Wihlborg; Abhishek Niroula; Bhairavi Swaminathan; Ellinor Johnsson; Owen W Stephens; Gareth Morgan; Tobias Meissner; Ingemar Turesson; Hartmut Goldschmidt; Ulf-Henrik Mellqvist; Urban Gullberg; Markus Hansson; Kari Hemminki; Hareth Nahi; Anders Waage; Niels Weinhold; Björn Nilsson
Journal:  Nat Commun       Date:  2018-04-25       Impact factor: 14.919

4.  Disease staging according to international scoring system in newly diagnosed patients with multiple myeloma.

Authors:  Saira Parveen Shaikh; Syed Muhammad Irfan; Sadia Sultan Sheikh
Journal:  Pak J Med Sci       Date:  2019 Jan-Feb       Impact factor: 1.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.